FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
FinalDose is a business in healthcare based in London, England, United Kingdom.
Profile
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
As a business in healthcare, FinalDose is listed here with the public details available about it.
Its base of operations is London, England, United Kingdom.
Directory data places it at the Spring 2026 stage.
Its team size is recorded as 5 employees.
Directory analysis
FinalDose is a UK‑based healthcare startup developing a programmable DNA‑targeting drug that can be customized to recognize and destroy cancer cells based on specific genetic sequences. The platform aims to address up to 80% of currently undruggable targets, starting with oncology applications. The company has a small team of five employees and is in the spring 2026 stage.
Positioning: The company is positioned at the intersection of precision oncology and synthetic biology, offering a novel approach to target hard‑to‑drug cancer mutations. As a very early‑stage venture with limited funding details, its commercial viability and regulatory pathway remain uncertain.
Note: FinalDose claims to create a single smart drug that can be programmed to kill cancer cells by DNA recognition.
Auto-generated directory analysis from public data · updated 8 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | London, England, United Kingdom |
| Country | United Kingdom |
| Employees | 5 |
| Stage | Spring 2026 |
Website: finaldose.ai
Browse related
Create a free account